Clinical applications of positron emission tomography in sarcoma management

There is no fulltext present in this item.

Title:	Clinical applications of positron emission tomography in sarcoma management
Author(s):	Quak, E.; Luijtgaarden, A.C.M. van de ; Geus-Oei, L.F. de ; van der Graaf, W.T. ; Oyen, W.J.G.
Publication year:	2011
Source:	Expert Review of Anticancer Therapy, vol. 11, iss. 2, (2011), pp. 195-204
ISSN:	1473-7140
DOI:	http://dx.doi.org/10.1586/era.10.133
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/96732
Display more details
Subject:	ONCOL 3: Translational research ONCOL 5: Aetiology, screening and detection
Organization:	Nuclear Medicine Medical Oncology
Journal title:	Expert Review of Anticancer Therapy
Volume:	vol. 11
Issue:	iss. 2
Page start:	p. 195
Page end:	p. 204
Abstract:	Positron emission tomography (PET) with the fluorine-18-labeled glucose analog FDG is a technique that noninvasively visualizes glucose metabolism in the human body. In oncology, the addition of FDG-PET to the conventional anatomical imaging techniques provides very useful clinical information in diagnosis, staging, treatment response monitoring and follow-up. In the heterogeneous group of patients with sarcoma, FDG-PET has been shown to be of great value in improving patient care. In this article we will discuss the current role of FDG-PET in the management of patients with sarcoma and its value in assessing tumor grade, guiding biopsy, staging, monitoring treatment response, restaging and prognostication. Our future expectation is that the value of PET will only augment owing to the implementation of FDG-PET in clinical guidelines, the increasing availability worldwide, and the development of new tracers and new hybrid imaging techniques.